CN101361745A - Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis - Google Patents
Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis Download PDFInfo
- Publication number
- CN101361745A CN101361745A CNA2008102223668A CN200810222366A CN101361745A CN 101361745 A CN101361745 A CN 101361745A CN A2008102223668 A CNA2008102223668 A CN A2008102223668A CN 200810222366 A CN200810222366 A CN 200810222366A CN 101361745 A CN101361745 A CN 101361745A
- Authority
- CN
- China
- Prior art keywords
- apoptosis
- cell
- mesenchymal stem
- group
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 68
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 201000002818 limb ischemia Diseases 0.000 claims abstract description 5
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 15
- 238000002054 transplantation Methods 0.000 abstract description 14
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 98
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000003952 Caspase 3 Human genes 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 206010002660 Anoxia Diseases 0.000 description 7
- 241000976983 Anoxia Species 0.000 description 7
- 230000007953 anoxia Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 230000006909 anti-apoptosis Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 241000594182 Sarcophaga sigma Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100156448 Caenorhabditis elegans vps-33.1 gene Proteins 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 108700010045 sry Genes Proteins 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses the application of S1P in preparing a medicament for inhibiting mesenchymal stem cells from apoptosis, in preparing a medicament for curing ischemic heart disease and a medicament for curing limb ischemia. The invention can significantly improve the survival rate of mesenchymal stem cells in clinical transplantation.
Description
Technical field
The invention belongs to biomedicine field, relate in particular to a kind of new purposes of S1P.
Background technology
(English name is 1-phosphoric acid sphingol: sphingosine 1-phosphate, be called for short S1P) be the sphingomyelins metabolite with biologic activity in serum source, has the important physical function, both can be used as that the second message,second messenger plays a role in the cell, and can combine with the special receptor of cell surface again and bring into play important biological function.1-phosphoric acid Chemistry of Sphingosine structural formula is:
Its molecular formula is: C
18H
38NO
5P, its molecular weight is: 379.47.200480037861.1) and " antilymphocyte antibody of combination S 1P receptor agonist/modulator and immunosuppressant is induced " (application number: some purposes that disclose S1P 200680003305.1) etc. at present, patent application " sphingosine-1-phosphate (S1P) receptor stimulating agent is used for the treatment of the application of brain degenerative diseases " (application number:.
For a long time, S1P is considered to the sphingolipid metabolite that forms in the eukaryotic cell membrane Umklapp process always.Yet, found that before 10 years it has regulated (Zhang since the cell growth, H etc. (1991) J.CellBiol.114,155-167), S1P has been in the news and has participated in many different biological processes, such as, the cell growth, differentiation, survival, blood vessel takes place and cell migration (Goetzl, E.J etc. (1998) FASEBJ.12,1589-1598.Spiegel, S. etc. (2000) Biochim.Biophys.Acta 1484,107-116.Pyne, S. etc. (2000) Biochem.J.349,385-402.Hla, T etc., (2001) Science 294,1875-1878).Recently find, S1P is by influencing the adjusting (Jolly that the transportation of T cell function and lymphocyte has participated in immunologic function equally, P. etc. (2002) Mol.Immunol.38,1239-1245.Mandala, S etc. (2002) Science 296,346-349.Brinkmann, V etc. and (2002) J.Biol.Chem.277,21453-21457).In addition, Aventis Pharma GmbH is at " purposes of S1P " (application number: disclose S1P and function fragment thereof 200480015055.4) in effects such as adjusting, prevention and eliminate pains.Playing the part of multiple player especially at cardiovascular system S1P, comprise myocardial cell (P.Robert etc., J.Mol.Cell.Cardiol.33 (2001) 1589-1606), cardiac fibroblast (Lucia Cavallini etc. by adjusting, Arch Biochem Biophys, Oct 1999; 370 (2): .Am J Physiol Heart Circ Physiol such as 156-62.Lee K, Jun2007; 292:H2698-H2711), blood vessel endothelium and vascular smooth muscle cell (Waeber C etc., Vascular sphingosine-1-phosphate SlP1 and S1P3 receptors.Drug NewsPerspect 2004,17:365-382.Tamama K etc., Okajima F:Sphingosine1-phosphate signaling in atherosclerosis and vascular biology.Curr OpinLipidol 2002,13:489-495.Panetti TS:Differential effects ofsphingosine 1-phosphate and lysophosphatidic acid on endothelial cells.Biochim Biophys Acta 2002,1582:190-196) at the hypertrophy of interior cell, propagation, the generation and the development of multiple physiology of cardiovascular system and pathophysiological processes regulated and control in survival and biological characteristics such as migration and then participation.
The M ﹠ M of myocardial infarction raises year by year, is having a strong impact on people's quality of life.The scheming infarction causes the generation of myocardial ischemia, and myocardial ischemia causes myocardial cell because of deficient the carrying out property death of nutrition, forms scar tissue then, and cardiac muscle takes place excessively to reinvent, finally cause heart failure (.RevInvest Clin such as JL Aceves, Mar 2005; 57 (2): 156-62).In recent years, the cellular transplantation therapy myocardial infarction has obtained development faster.The mescenchymal stem cell of derived from bone marrow (mesenchymal stem cells, hereinafter to be referred as MSCs) can be used as seed cell and be transplanted to ischemic myocardium, itself and by being differentiated to form myocardial cell, approach such as paracrine action improve ischemic myocardium blood effectively and supply, part recover and improved cardiac function (.Ann.Thorac.Surg. such as Kimikazu Hamano, Apr 2002; 73:1210-1215.JuliaFeygin Deng .Am J Physiol Heart Circ Physiol, Sep 2007; 293:H1772-H1780).At present, the MSCs cell transplantation has become safe and effective method (the Haider H.Expert Rev Cardiovasc Ther.2006 of domestic and international clinical treatment ischemic heart desease; 4 (4): 557-568.Monolayered mesenchymalstem cells repair scarred myocardium aftermyocardial infarction.Y Miyahara etc., Apr 2006; 12 (4): 459-65).Yet, discover that the MSCs that is implanted into the heart infarction district has only part to survive and to play a role, have a considerable amount of stem cell in ischemic tissue a large amount of apoptosis (Dec 2003 for YONG-JIAN GENG etc., Acad.Sci.; 1010:687～697).Therefore, how effectively to reduce the MSCs apoptosis rate that is implanted into ischemic tissue, improve its survival rate, thereby reach best cellular transplantation therapy effect, be the difficult problem that present cellular replacement therapy ischemic heart desease and other ischemic disease of limb need to be resolved hurrily, and directly have influence on the curative effect of cell transplantation.
By retrieval, do not find that relevant S1P suppresses the report of apoptosis of mesenchymal stem cell effect under the Hypoxia and ischemia environment.
Summary of the invention
Shortcomings such as the survival rate of seed cell-mesenchymal stem cells MSCs that The present invention be directed to present clinical cellular transplantation therapy ischemic cardiomyopathy is low, therapeutic effect difference provide a kind of medicine that can improve the mesenchymal stem cells MSCs survival and then strengthen its curative effect.
First purpose of the present invention is the application of S1P on preparation inhibition apoptosis of mesenchymal stem cell medicine.
Second purpose of the present invention is the application of S1P on preparation treatment ischemic heart medicine.
The 3rd purpose of the present invention is the application of S1P on preparation treatment ischemic disease of limb medicine.
Described S1P is meant S1P or contains the pharmaceutical composition of S1P.Described S1P (sphingosine1-phosphate is called for short S1P), Chinese is a 1-phosphoric acid sphingol, its chemical structural formula is:
Molecular formula is: C
18H
38NO
5The P molecular weight is: 379.47
Above-mentioned apoptosis of mesenchymal stem cell mainly is to be caused by the hypoxic-ischemic environment after transplanting, and described hypoxic-ischemic environment comprises that scarce (low) oxygen lacks (low) blood, lacks (low) oxygen intact (low) blood, lacks (low) blood intact (low) oxygen etc.
S1P of the present invention can obtain by buying, and is dissolved as desired concn (0.1～50%) with methanol or BSA etc. during use and gets final product.
The occupation mode of S1P among the present invention: (1), before transplanting, mesenchymal stem cells MSCs is hatched 20～120min in concentration is the S1P of 0.1～50uM; (2), before Bone Marrow Mesenchymal Stem Cells Transplantation, give the oral S1P of patient or contain the medicine of S1P, as high density lipoprotein (HDL) and low density lipoprotein, LDL (LDL); (3), before Bone Marrow Mesenchymal Stem Cells Transplantation, give patient's intravenous injection S1P or contain the medicine of S1P, improve the S1P content in the serum, as high density lipoprotein (HDL) and low density lipoprotein, LDL (LDL) etc.
The advantage that the present invention has: (1) the present invention is effective, can significantly improve the survival rate (survival rate can improve 50%) of the mesenchymal stem cells MSCs that clinical transplantation is used for the treatment of; (2) applied range of the present invention not only can be used for transplanting mescenchymal stem cell treatment ischemic heart desease, also can be used for ischemic disease of limb etc.
Description of drawings
Fig. 1. the nuclear fluorescence microscope photo of different disposal mesenchymal stem cells MSCs.
A wherein: normal control group, B: apoptosis model group, C:0.1 μ M S1P+ apoptosis model group,
D:1 μ M S1P+ apoptosis model group, E:10 μ M S1P+ apoptosis model group,
F:20 μ M S1P+ apoptosis model group, G:50 μ M S1P+ apoptosis model group.
Fig. 2. different disposal mesenchymal stem cells MSCs Annexin V/PI Flow cytometry result.
A wherein: normal control group, B: apoptosis model group, C:S1P0.1 μ M+ apoptosis model group,
D:S1P 1 μ M+ apoptosis model group, E:S1P 10 μ M+ apoptosis model group, F:S1P 20 μ M+ apoptosis model group, G:S1P 50 μ M+ apoptosis model group.
Fig. 3. the column cartogram of different disposal apoptosis of mesenchymal stem cell rate
A wherein: normal control group, B: apoptosis model group, C:S1P 0.1 μ M+ apoptosis model group, D:S1P 1 μ M+ apoptosis model group, E:S1P 10 μ M+ apoptosis model group, F:S1P 20 μ M+ apoptosis model group, G:S1P 50 μ M+ apoptosis model group.
Fig. 4. different disposal is to the western blot figure of caspase-3 activation fragment influence.
Wherein 1: normal control group, 2: apoptosis model group, 3:S1P (10 μ M)+apoptosis model group, 4:S1P (10 μ M)+apoptosis model group+LY294002 (25uM), 5:S1P (10 μ M)+apoptosis model group+U0126 (20uM).
Fig. 5. for detecting the western blot figure that S1P activates the PI3K/Akt signal path.
Wherein 1: normal control group, 2: apoptosis model group, 3:S1P (10 μ M)+apoptosis model group, 4:S1P (10 μ M)+apoptosis model group+LY294002 (25uM), 5:S1P (10 μ M)+apoptosis model group+U0126 (20uM)
Fig. 6. for detecting the western blot figure that S1P activates the MEK/ERK1/2 signal path.
Wherein 1: normal control group, 2: apoptosis model group, 3:S1P (10 μ M)+apoptosis model group, 4:S1P (10 μ M)+apoptosis model group+LY294002 (25uM), 5:S1P (10 μ M)+apoptosis model group+U0126 (20uM)
Fig. 7. the comparison diagram of survivaling cell number behind the Bone Marrow Mesenchymal Stem Cells Transplantation ischemic myocardium of different disposal.
Wherein vertical coordinate is a survival cells, and abscissa is the natural law of cell transplantation.
The specific embodiment
Below in conjunction with drawings and Examples wood invention is described further, but following specific embodiments only illustrates, but not limit protection scope of the present invention by any way.
Carry out as follows
(1), MSCs separates and cultivates
Take the Sprague-Dawley rat, male and female are regardless of, after ketalar (60-80mg/kg) intraperitoneal anesthesia, and 75% alcohol-pickled sterilization 3～5 minutes; Clip rat femur and tibia in super-clean bench, wash medullary cavity 10 times with complete medium (IMDM+15%FBS) (IMDM and FBS are all available from Gibcol biotech firm), inhale repeatedly with micro pipette and blow bone marrow, form dispersive single cell suspension, be inoculated in the culture bottle, put 37 ℃, 5%CO
2Cell culture incubator is cultivated; Cell can grow to more than 80% and to merge after 5 days, with 1:3 (0.25% pancreatin) (pancreatin is available from Sigma-Aldrich company) of going down to posterity; Getting well-grown first generation cell experimentizes.
(2), experiment grouping and processing
A. normal control group: (IMDM+15%FBS) normally cultivates MSCs with complete medium;
B. apoptosis model group: with serum-free (IMDM) and anoxic treatment MSCs (placing the airtight anoxia jar, built-in oxygen consumption agent), 37 ℃, 5%CO
2Hatched 6 hours;
C.S1P processed group: be the S1P (available from U.S. Sigma-Aldrich company) pretreatment MSCs1 hour of 0.1 μ M, 1 μ M, 10 μ M, 20 μ M, 50 μ M with concentration respectively, under the anoxia serum-free condition, continued to hatch 6 hours then.The preparation method of described S1P is that S1P is dissolved in methanol, and then is diluted to desired concn with BSA and gets final product; As 1mg S1P is dissolved in the 263.5ul methanol, reach the liquid storage of 10uM, diluting respectively with 0.4%BSA then is 0.1 and the concentration of 1uM (when using 20uM, during 50uM, the S1P dosage that adds 2 times and 5 times respectively gets final product).
(3), the variation of observation of cell nuclear under the fluorescence microscope
After the MSCs cell is respectively organized in above-mentioned (2) processing, fix 30 minutes with the PBS room temperature that contains 1% glutaraldehyde, to wash 2 times with PBS then, reuse 5 μ g/ml Hoechst 33342 room temperatures are fixed 30 minutes, the nuclear form of observing apoptosis under the fluorescence microscope.
Big and the homogenizing of normal control group (seeing Figure 1A) nucleus as a result, pale blue dyeing; Apoptosis model group (seeing Figure 1B) and 0.1 μ M S1P processed group (seeing Fig. 1 C) karyopyknosis, cracked, form is irregular, and dyeing is dark; 1 μ M, 10 μ M, 20 μ M, 50 μ M S1P processed group (seeing Fig. 1 D-G) nucleus are examined big and homogenizing, pale blue dyeing like the normal control group.Illustrate that S1P can suppress the nucleus generation apoptosis form change of mesenchymal stem cells MSCs, promptly S1P can suppress the generation of MSCs apoptosis.
Embodiment 2, apoptosis of mesenchymal stem cell rate detect test
Test method is as follows:
(1) the experiment grouping is with embodiment 1.
(2) according to Annexin V/PI apoptosis detection kit (Beijing Bao Sai Bioisystech Co., Ltd) explanation, to respectively organize cell with what gained was handled in trypsinization among the embodiment 1, wash 2 times with cold PBS, reuse Annexin V solution incubated at room 30 minutes, then add PI solution and hatched 5 minutes, (the Annexin-V/PI streaming detects early apoptosis and the middle and advanced stage apoptosis that can distinguish cell to up flow type cell instrument detection apoptosis rate then.PS during early apoptosis on the cell membrane translates into the cell membrane skin outward, shows as the Annexin-V positive, but cell membrane is complete, and PI is negative, and wherein Annexin V+/PI-represents early stage apoptosis).
The normal control group is (as Fig. 2 A as a result, Fig. 3 A) early apoptosis rate is 2.03%, apoptosis model group (Fig. 2 B, Fig. 3 B) apoptosis rate is 31.28%, 0.1uM, the early apoptosis rate of each processed group of S1P of 1uM, 10uM, 20uM, 50uM concentration is (as Fig. 2 C-G, Fig. 3 C-G) be respectively 28.29%, 22.91%, 13.12%, 9.97%, 10.86%, the early apoptosis rate that adds each processed group of S1P all is lower than the apoptosis model group.The S1P that variable concentrations is described all can effectively suppress the MSCs apoptosis.
Embodiment 3, S1P are to the test of caspase-3 effect of vigor
(1) test is handled:
(a) normal control group: cultivate so that complete medium (IMDM+15%FBS) is normal; (b) apoptosis model group: with serum-free (IMDM) and anoxic treatment (placing the airtight anoxia jar, built-in oxygen consumption agent), 37 ℃, 5%CO
2Hatched 6 hours; (c) S1P (available from U.S. Sigma company) processed group:, under the anoxia serum-free condition, continued to hatch 6 hours then with the S1P pretreatment of 10uM MSCs1 hour; (d) S1P (10 μ M)+apoptosis model+LY294002 (25uM) organizes (LY294002 is available from cellsignal company); (e) S1P (10 μ M)+apoptosis model group+U0126 (20uM) organizes (U0126 is available from cellsignal company).
(2) test method: each organized the cell non-serum anoxia after 6 hours, and pancreatin (0.25%) digestion, collecting cell extract cell protein, survey protein concentration with the Coomassie brilliant blue method.By sample electrophoresis on the 50 μ g albumen qualities, Western blot (seeing molecular cloning second edition the 18 chapter the 3rd joint 888-898 page or leaf for details) detects caspase-3 activation fragment
The MSC of normal control group (Fig. 4-1) does not almost have Caspase3 to activate segmental generation as a result; And apoptosis model group (Figure 42) has a large amount of Caspase3 activation fragments to produce; The Caspase3 activation fragment of S1P processed group (Fig. 4-3) significantly reduces; After using PI3K and ERK inhibitor LY294002 and U0126 (Fig. 4-4,5) to suppress these two paths, Caspase3 activation fragment increases than S1P processed group again.Illustrate that S1P activates the apoptosis that segmental generation has suppressed MSCs by suppressing Caspase3.
(1) test is handled: (a) normal control group: cultivate so that complete medium (IMDM+15%FBS) is normal; (b) apoptosis model group: with serum-free (IMDM) and anoxic treatment (placing the airtight anoxia jar, built-in oxygen consumption agent), 37 ℃, 5%CO
2Hatched 6 hours; (c) S1P (available from U.S. Sigma company) processed group:, under the anoxia serum-free condition, continued to hatch 6 hours then with the S1P pretreatment MSCs of 10uM 1 hour.(d) S1P (10 μ M)+apoptosis model+LY294002 (25uM) group; (e) S1P (10 μ M)+apoptosis model group+U0126 (20uM) group.
(2), above-mentioned respectively organize the cell processing and finish after, the up flow type cell instrument detects PI3K inhibitor LY294002 and/or the ERK1/2 inhibitor U0126 influence to the anti-apoptotic effect of S1P.
Result (as Fig. 5 and Fig. 6) illustrates that LY294002 and U0126 all can obviously suppress the anti-apoptosis of mesenchymal stem cell effect of S1P.PI3K and ERK pathway inhibitor LY294002 and U0126 all can suppress the anti-apoptosis of mesenchymal stem cell effect of S1P separately, also side light the anti-apoptosis of mesenchymal stem cell effect of S1P.
Embodiment 5
The animal experiment of the short mesenchymal stem cells MSCs survival effect of S1P
(1), test is handled:
A. matched group: cultivate (IMDM contains L-glutaminate and 25mM HEPES) 50ul injection rat heart infarction model heart infarction surrounding zone with complete medium;
B.S1P processed group: cultivate (IMDM) 50ul with the complete medium that contains S1P and suspend 2 * 10
6Mescenchymal stem cell, pretreatment 1h (the S1P final concentration is 10uM).Then inject rat heart infarction model heart infarction surrounding zone together;
(2), test method: the mode of male rat mesenchymal stem cells MSCs injection female rats heart infarction model is adopted in test, 3 groups back 1 hour respectively in injection, 1 day and 1 week back extraction heart tissue DNA pass through to detect the content of sry gene and then detect the mescenchymal stem cell number of surviving with the method for Realtime PCR then.
After 1 hour, the number of the MSC of matched group survival is 490939.3615 to (see figure 7) at cell transplantation as a result, and S1P processed group cell survivaling number is 1051256.348, apparently higher than matched group; Behind the cell transplantation 1 day, the number of the MSC of matched group and the survival of S1P processed group is respectively 331059.9 and 682976.6, and the MSCs number of S1P processed group survival also is significantly higher than matched group; Cell transplantation is after 1 week, and the number of the MSC of S1P processed group survival is 27721.43, is higher than mescenchymal stem cell group 13357.12.Explanation S1P in experimental animals has significantly improved the survival rate of transplanting MSC.
Claims (4)
1, the application of S1P on preparation inhibition apoptosis of mesenchymal stem cell medicine.
2, the application of S1P on preparation treatment ischemic heart medicine.
3, the application of S1P on preparation treatment ischemic disease of limb medicine.
4,, it is characterized in that described S1P is meant S1P or contains the compositions of S1P according to claim 1,2 or 3 described application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102223668A CN101361745B (en) | 2008-09-17 | 2008-09-17 | Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102223668A CN101361745B (en) | 2008-09-17 | 2008-09-17 | Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101361745A true CN101361745A (en) | 2009-02-11 |
| CN101361745B CN101361745B (en) | 2011-09-14 |
Family
ID=40388473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102223668A Expired - Fee Related CN101361745B (en) | 2008-09-17 | 2008-09-17 | Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361745B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105188754A (en) * | 2013-03-01 | 2015-12-23 | 株式会社Ｃｌｉｏ | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury |
| CN110462023A (en) * | 2016-11-10 | 2019-11-15 | 蔚山大学校产学协力团 | It include the Stem Cell Activity composition for promoting of histon deacetylase (HDAC) inhibitor and activity factor as effective component |
| CN115961056A (en) * | 2022-12-21 | 2023-04-14 | 武汉光谷中源药业有限公司 | Method for detecting content of umbilical cord source mesenchymal stem cells in human whole blood |
-
2008
- 2008-09-17 CN CN2008102223668A patent/CN101361745B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105188754A (en) * | 2013-03-01 | 2015-12-23 | 株式会社Ｃｌｉｏ | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury |
| US10034889B2 (en) | 2013-03-01 | 2018-07-31 | Clio, Inc. | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to damage |
| US10369162B2 (en) | 2013-03-01 | 2019-08-06 | Clio, Inc. | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to damage |
| CN110462023A (en) * | 2016-11-10 | 2019-11-15 | 蔚山大学校产学协力团 | It include the Stem Cell Activity composition for promoting of histon deacetylase (HDAC) inhibitor and activity factor as effective component |
| CN110462023B (en) * | 2016-11-10 | 2024-01-09 | 蔚山大学校产学协力团 | Stem cell activity promoting composition comprising histone deacetylase inhibitor and activator as active ingredients |
| CN115961056A (en) * | 2022-12-21 | 2023-04-14 | 武汉光谷中源药业有限公司 | Method for detecting content of umbilical cord source mesenchymal stem cells in human whole blood |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101361745B (en) | 2011-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11441124B2 (en) | Mammalian cells enriched with functional mitochondria | |
| Han et al. | Optimization of human umbilical cord mesenchymal stem cell isolation and culture methods | |
| US20100129330A1 (en) | Adipocytic differentiated adipose derived adult stem cells and uses thereof | |
| KR101578591B1 (en) | Cell Therapy Composition for Preventing or Treating Immune Disease Comprising Mesenchymal Stem Cells and Immunoregulatory T-cells as active ingredient | |
| Zhao et al. | Mesenchymal stem cell transplantation improves regional cardiac remodeling following ovine infarction | |
| CN103930542A (en) | Brown fat cell compositions and methods | |
| CN101361745B (en) | Use of SIP in preparing medicine for preventing mesenchymal stem cells apoptosis | |
| Madonna et al. | Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion | |
| Kowalski et al. | Hypoxic culture conditions induce increased metabolic rate and collagen gene expression in ACL‐derived cells | |
| CN114214272A (en) | Method for inducing umbilical cord mesenchymal stem cells to differentiate cardiomyocytes, culture medium and application of culture medium | |
| CN106148276A (en) | Application in the medicine of preparation treatment nerve degenerative diseases for the mescenchymal stem cell | |
| Li et al. | An improved two-step method for extraction and purification of primary cardiomyocytes from neonatal mice | |
| US11834679B2 (en) | Method for producing cardiomyocytes | |
| CN107151263A (en) | A kind of small peptide inhibitor for suppressing amylin aggregation | |
| US10017740B2 (en) | Deriving brown adipose tissue cells | |
| Li et al. | Effect of NRG-1/ErbB Signaling Intervention on the Differentiation of Bone Marrow Stromal Cells Into Sinus Node–like Cells | |
| BR112020026531A2 (en) | METHOD TO GENERATE A POPULATION OF ACTIVATED ISLET PROLIFERATIVE CELLS, AND, COMPOSITION | |
| JP2016204302A (en) | Islet transplantation using dental pulp stem cell | |
| Yao et al. | Effect of various ratios of co‐cultured ATDC5 cells and chondrocytes on the expression of cartilaginous phenotype in microcavitary alginate hydrogel | |
| Tanaka et al. | Prolonged survival of mice with acute liver failure with transplantation of monkey hepatocytes cultured with an antiapoptotic pentapeptide V5 | |
| CN107056895A (en) | The artificial polypeptide and its biological products of inducing bone mesenchymal stem cell into hepatocyte differentiation | |
| CN102727505A (en) | Application of salidroside in preventing and treating amyotrophy diseases | |
| JP5822189B2 (en) | Differentiation induction promoter from stem cells to brown adipocytes | |
| US11788062B2 (en) | Functional feline pancreatic cells from adipose tissue | |
| KR102665916B1 (en) | novel uses of ENPL genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20140917 |
|
| EXPY | Termination of patent right or utility model |